ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Monday, November 18, 2024

9:00AM-10:30AM: Abstract Number: 2528

Activation of the Hes1/Piezo1 Pathway Promotes Mechanical Stress Response and Prevents Glucocorticoid-induced Osteoporosis

Plenary III

9:00AM-10:30AM: Abstract Number: 2531

CRISPR Deletion Screen in Fibroblasts Identifies Novel Regulators of Inflammation

Plenary III

9:00AM-10:30AM: Abstract Number: 2527

Efficacy and Safety of Nipocalimab, an Anti-FcRn Monoclonal Antibody, in Primary Sjogren’s Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study (DAHLIAS)

Plenary III

9:00AM-10:30AM: Abstract Number: 2529

Improving Outcomes and Narrowing Disparities in Juvenile Idiopathic Arthritis (JIA): A Division-Wide, Equity-Focused Quality Improvement Project

Plenary III

9:00AM-10:30AM: Abstract Number: 2532

Mortality in Patients with Pre-existing Autoimmune Disease on Immune Checkpoint Inhibitor Therapy

Plenary III

9:00AM-10:30AM: Abstract Number: 2530

Single-cell Multi-omics Analysis of Reactive Lymph Nodes, Affected Tissues, and Blood Reveals a Naive-like CD4+TRAIL+ T Cell Population That Differentially Directs Effector Anti-nuclear Antigen Reactive Responses in Patients with Sjogren’s Syndrome and Systemic Sclerosis

Plenary III

10:30AM-12:30PM: Abstract Number: 1855

Identification of Autoreactive Cytotoxic T Cells in ANCA-Associated Vasculitis

T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

10:30AM-12:30PM: Abstract Number: 2363

“How Quickly Will I Feel Better with This New Drug?” – Rapidity of Treatment Response in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Analysis from Two Phase 3 Studies

SpA Including PsA – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2154

“I Have Taken Five Different Kinds of Tablets and Injections, and I Still Have Foot Pain”: An International Outcome Measures in Rheumatology (OMERACT) Qualitative Study Exploring Patient Perspectives of Foot and Ankle Disorders

Patient Outcomes, Preferences, & Attitudes Poster III

10:30AM-12:30PM: Abstract Number: 1882

30-Day Readmission Among Patients with Rheumatoid Arthritis and Their Independent Predictors: Insights from National Readmission Database

Epidemiology & Public Health Poster III

10:30AM-12:30PM: Abstract Number: 1959

A 3-arm, Randomized, Open-label, Parallel Active Controlled, Multicentre International Study to Compare the Response of Ultrasound-assessed Synovitis to Baricitinib, Alone and Combined with Methotrexate versus Etanercept in Rheumatoid Arthritis Patients

Imaging of Rheumatic Diseases Poster II

10:30AM-12:30PM: Abstract Number: 2031

A Contemporary Assessment of the Burden of Malignancy in IgG4-Related Disease

Miscellaneous Rheumatic & Inflammatory Diseases Poster III

10:30AM-12:30PM: Abstract Number: 2243

A Cross-sectional Study of the Association Between Anxiety State and Various Factors in Patients with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2242

A Cross-sectional Study on Predictors of COVID-19 Infection, Admission and Mortality and Effect of Immunomodulating Treatments in Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2099

A Longitudinal Study of Infrapatellar Fat Pad Morphologies as Predictive Markersin Knee Osteoarthritis

Osteoarthritis – Clinical Poster II

1
2
3
…
61
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].